Cerebrovasular imaging company iSchemaView has received the FDA nod for its latest product the RAPID CTA, a 3D imaging platform for computed tomogrpahy angiography (CTA). 

“Our goal is to provide healthcare professionals around the world with the most comprehensive and intuitive suite of imaging solutions possible,” Don Listwin, CEO of iSchemaView, said in a statement. “With new FDA approval and the release of RAPID CTA, we are making good on that goal. We ensure physicians can take advantage of RAPID’s power whether they choose plain CT, CT Angiography, CT Perfusion, or MR diffusion and perfusion. It’s all about offering them the right imaging solution choice, for the right patient at the right time.”

CTA scans are used to help clinicians visualize their patients' cerebral arteries, usually if a patient has experienced a blood clot, according to the company. But interpreting the standard output can be a time-consuming process, it says.  

This technology is able to give doctors a complete view of blood vessels in the brain and lets doctors rotate the images in different angles. The CT maps also have four colored overlays so that doctors and caregivers can see which regions of the brain have reduced blood vessel density. It only takes a few minutes for the image to be ready to read. 

The tool was designed to help physicians with clinical decision making and patient triage. It was also intended to help with collaborations between community hospitals and specialists, and to help doctors decide the appropriate patient transfers to speciality centers.  

The CTA scans can be used on a mobile app or on any computer web browser. Clinicians can view the results remotely or in the hospitals. 

“Many eligible stroke patients with large vessel occlusions must be quickly transferred to a comprehensive stroke center. The new automated RAPID CTA tool makes it easy for community hospitals to quickly identify potential candidates for treatment and for experts at the comprehensive centers to verify that the patient is appropriate for transfer,” Greg Albers, professor of neurology at Stanford University, director of the Stanford Stroke Center, and cofounder of iSchemaView, said in a statement. “With the addition of CTA to RAPID’s FDA indications, hospitals and clinics of all sizes and locations can now use the platform to immediately review images from wherever they are. That’s powerful.”

iSchemaView also has an imaging product for MRI and CTP scans.